MelindaSMerchantMDPhD
Pediatric Hematology & Oncology • Bethesda, MDPediatric Oncology Branch, National Cancer Institute
Dr. Merchant is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
10 Center Dr Bldg 10-CRC
Bethesda, MD 20892Phone+1 301-443-7955- Is this information wrong?
Education & Training
Johns Hopkins UniversityFellowship, Pediatric Hematology/Oncology, 1999 - 2002
Children's National Medical CenterResidency, Pediatrics, 1996 - 1999
University of Miami Leonard M. Miller School of MedicineClass of 1996
Certifications & Licensure
NY State Medical License 2005 - 2024- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- A Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents and Young Adults With Treatment Refractory Cancer Start of enrollment: 2007 Oct 01
- A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma Start of enrollment: 2012 Sep 27
- Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer Start of enrollment: 2007 Oct 01
Publications & Presentations
PubMed
- 2 citationsImmune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy.Sabina Kaczanowska, Tara Murty, Ahmad Alimadadi, Cristina F Contreras, Caroline Duault, Priyanka B Subrahmanyam, Warren Reynolds, Norma A Gutierrez, Reema Baskar, Cath...> ;Cancer Cell. 2024 Jan 8
- 22 citationsBrain exposure of the ATM inhibitor AZD1390 in humans-a positron emission tomography study.Aurelija Jucaite, Per Stenkrona, Zsolt Cselényi, Serena De Vita, Núria Buil-Bruna, Katarina Varnäs, Alicia Savage, Andrea Varrone, Peter Johnström, Magnus Schou, Chris...> ;Neuro-Oncology. 2021 Apr 12
- 8 citationsEvaluation of Combination Strategies for the A2AR Inhibitor AZD4635 Across Tumor Microenvironment Conditions via a Systems Pharmacology Model.Veronika Voronova, Kirill Peskov, Yuri Kosinsky, Gabriel Helmlinger, Lulu Chu, Alexandra Borodovsky, Richard Woessner, Kris Sachsenmeier, Wenlin Shao, Rakesh Kumar, Ga...> ;Frontiers in Immunology. 2021 Mar 2
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
